China produces approximately 75% of specialty enzymes and amino acids used in US food ingredient manufacturing. The Food Ingredient & Additive Council sent a formal letter to President Trump flagging supply security risk from this concentration. With tariffs active and escalating, this has moved from a strategic concern to an active operational problem for every formulator in your readership. Your December 2025 market outlook piece noted it in passing. No standalone feature exists anywhere in trade press addressing what formulators and procurement teams should be doing right now.
The joint venture combining Novatek Ingredients and Celara Sciences' North American specialty ingredient manufacturing operations closed Q1 2026, creating a Top 3 North American producer. As of late 2025 the combined entity name had not been publicly announced — meaning the first full profile has not been written by any trade title. Your December 2025 outlook piece mentioned the JV in passing. The standalone profile — combined facilities, leadership, formulation philosophy, competitive implications — remains unwritten.
The Food Safety Authority has issued an emergency alert on a novel adulterant detected in imported specialty ingredient batches. Policy and food safety titles are covering the regulatory response. Formulation & Supply has a dedicated food safety section and no coverage despite this directly affecting sourcing and QC protocols for your readership. Contamination events disrupt procurement pipelines, supplier qualification timelines, and customer delivery commitments — all squarely in the formulator's operational world.
The Global Ingredient Council's annual market sizing report shows functional protein volume up 8.4% globally, driven by a structural shift from commodity to specialty-grade production — not just demand expansion. Formulation & Supply has covered past editions and owns the Top Ingredient Suppliers franchise. The 2026 edition has been picked up by food science and commodity titles. Your feature anchored to the manufacturing and sourcing implications hasn't yet appeared.
Harvestin BV, a European functional ingredient group, has entered into an agreement to acquire Processa Ingredientes, a Brazilian specialty processor, establishing its first presence in the Southern Hemisphere. Brazil is among the world's top-three ingredient-producing markets. No coverage found in Formulation & Supply, Food Ingredient First, or any competing trade title.
Formulation & Supply covered the Ingredient Transparency Act's introduction at the House level in 2024. The legislation — which would allow specialty ingredient manufacturers to claim functional benefits, closing the competitive gap with European and South American producers — is a stated 2026 priority for both FIAC and the Global Ingredient Council with bipartisan support. No 2026 status and implications piece appears in your archive.
FIAC announced dedicated 2026 programming on rapid contaminant detection methods. Formulation & Supply's own top-read 2025 content includes molecular-level detection techniques. Confirmed audience engagement in your analytics plus confirmed industry programming is a rare combination.
A dedicated IFT session covered connecting inventory, procurement, batch records, and delivery platforms without adding new software layers. Formulation & Supply has operations coverage but the specific "connect what you already have" angle for plant managers hasn't been written.
The 2026 Upcycled Ingredients Symposium focused on science-based communication for byproduct-derived ingredients and their role in a sustainable supply chain. As alternative proteins compete for the sustainability narrative, upcycled ingredients' story needs to be retold in the data language Formulation & Supply already uses for carbon and circularity coverage.
Multiple 2026 events including IFT FIRST and FIAC programming are featuring precision delivery and bioavailability sessions. Formulation & Supply has strong authority in this space from nutrition science coverage but coverage is episodic rather than structured.
Every manufacturer in your readership is affected right now. The policy story is being covered by commodity and food science titles. The piece nobody has written — from any trade title — is the formulator response guide: which categories carry the most supply risk, what substitution strategies are available, how procurement teams should be adjusting now. That is unambiguously Formulation & Supply's lane and the window to own it is narrowing.
The combined entity name hasn't been publicly announced — so the race to publish the first full profile hasn't started yet. Formulation & Supply mentioned the JV in the December 2025 outlook. Getting on the record with sources at both Novatek and Celara Sciences now means you publish the definitive profile immediately when the name drops, not two weeks later. This is a cover story for whichever trade title gets there first.
Regulatory and food safety titles are covering the contamination alert and its regulatory response. Formulation & Supply has a dedicated food safety section and no coverage. The angle that no title has written: what does this contamination event mean for ingredient manufacturers operationally — procurement adjustments, QC protocol changes, customer communication strategy? That's the thread that makes a widely covered story into a distinctly Formulation & Supply story.
Formulators, plant managers, procurement leads, and ingredient buyers are all directly affected. A well-structured feature with a practical sourcing guide has the profile of your highest-engagement content — specific, actionable, timely, written from the manufacturer's operational perspective. No competing coverage yet.
The Top Ingredient Suppliers franchise already establishes Formulation & Supply's ownership of industry structure coverage. The first full profile of the largest consolidation event in North American specialty ingredients in years belongs here — and advertisers serving both Novatek and Celara customers have a clear reason to be adjacent to this coverage.
Conference demand is building across multiple 2026 venues. Your nutrition science team has the authority. A structured column or bimonthly series would establish consistent ownership of a topic where practitioner demand is clearly growing — and creates a predictable advertising adjacency for delivery system and bioavailability ingredient companies.
The signals here are built from public data. The next version of this brief — built on Formulation & Supply's own engagement data — would surface which of these topics are already driving reader behavior, which content clusters are converting anonymous visitors to registered users, and where audience intent and advertiser interest intersect. That's what turns editorial intelligence into publishing strategy.
Imagine this for every title in your portfolio, every month. Automated signal collection across industry press releases, conference agendas, M&A activity, and regulatory filings — synthesized into a prioritized editorial brief your editors can act on before issue planning. Not another dashboard to check. A report that lands in your inbox and tells you what the industry is moving toward before your audience asks for it.
The version you're reading was built entirely from public data. The next version is built on yours — which topics are driving registrations, which content clusters attract your highest-value readers, where audience intent and advertiser interest intersect. That's what turns an editorial brief into a publishing strategy.
Learn about the full platform › mindful.pub